| Title |
Simeprevir for the treatment of hepatitis C virus infection
|
|---|---|
| Published in |
Pharmacogenomics and Personalized Medicine, August 2014
|
| DOI | 10.2147/pgpm.s52715 |
| Pubmed ID | |
| Authors |
Laure Izquierdo, François Helle, Catherine François, Sandrine Castelain, Gilles Duverlie, Etienne Brochot |
| Abstract |
Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is highly effective and safe, with few adverse events. We discuss the specific features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, will be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be part of future treatment strategies. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 6 | 60% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 66 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 19% |
| Student > Ph. D. Student | 10 | 15% |
| Student > Bachelor | 8 | 12% |
| Researcher | 7 | 10% |
| Student > Doctoral Student | 4 | 6% |
| Other | 9 | 13% |
| Unknown | 16 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 25% |
| Biochemistry, Genetics and Molecular Biology | 9 | 13% |
| Agricultural and Biological Sciences | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Immunology and Microbiology | 2 | 3% |
| Other | 8 | 12% |
| Unknown | 18 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2023.
All research outputs
#2,089,578
of 25,748,735 outputs
Outputs from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Outputs of similar age
#20,203
of 240,939 outputs
Outputs of similar age from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.4. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,939 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them